🔗 Share this article

As the US undertakes sweeping adjustments to its vaccination schedules, an unexpected name has surfaced unexpectedly: Høeg, an American of Danish descent sports medicine doctor and epidemiologist who initially gained attention by expressing skepticism about COVID-19 vaccinations in the global health crisis and has focused upon possible deaths after Covid immunization in her brief tenure at the Food and Drug Administration.

Proposed Shifts to Childhood Vaccine Schedule

Agency leaders had intended to announce major changes to the pediatric vaccination calendar earlier this month, bringing the US with Denmark’s vaccine program, it is understood – a substantial departure that would put the US at odds with much of the global community with no evidence for public health gain. This reveal has been pushed back until the next year.

Rather than Vinay Prasad, Dr. Høeg is listed to speak at the event. She was newly appointed temporary leader of the FDA’s CDER, the fifth appointee to lead the office this calendar year.

A New Direction at the FDA

The acting appointment might represent a tighter collaboration between the drug and biologics centers as Høeg and Dr. Prasad strengthen their influence at the regulatory agency – and it points to a increased emphasis upon dismantling previously authorized immunizations at the FDA.

Høeg has repeatedly called for discontinuing specific childhood vaccine recommendations in the US to become more in line with Denmark's approach, a society with universal health coverage and a population approximately the size of the state of Wisconsin.

To date comments, she has continued to focus on vaccination policy – traditionally the responsibility of Dr. Prasad, director of the FDA’s CBER – instead of pharmaceutical oversight.

Questions Over Background

Dr. Høeg has no obvious experience in pharmaceutical research, approval processes or management, which has been customary for former directors of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a top consultant to the FDA chief and CBER since March.

“She appears not to have the requisite experience” for running the drug-regulation department, said Dr. Jonathan Howard. “She has not conducted a clinical trial. She has no expertise in managing a sizeable institution. She lacks background in industry regulation.”

Former directors of the center would “understand legal statutes and the underlying principles of medication creation”, said Dr. Janet Woodcock. “Objectively, she doesn’t have the kind of background that prior appointees who headed the center have had.”

The drug center has an immense range of responsibilities at the agency, Woodcock stated.

“The public just focuses on the innovative therapies, but the generic drug division approves a multitude of generic drugs. There is also a biologic copycat branch, OTC medication office and so forth, and all of those have to be managed,” Woodcock noted. “The thing you neglect, that is precisely what that I always told people is going to cause problems.”

Additionally, a major administrative element to the role, which supervises in excess of 5,000 personnel. “It is a enormous management job, if you execute it properly,” Woodcock said.

Agency Reaction and Disputed Initiatives

Regarding inquiries about Høeg’s qualifications and whether this appointment signifies more teamwork among regulatory chiefs on vaccines, a spokesperson said that the “questions stem from flawed premises”.

“Her resume matches the functions of her position,” the official said, noting the period Høeg spent advising the agency head on “medication safety and approval science, including predictive safety algorithms and immunization monitoring”.

As the temporary head, Dr. Høeg takes over the commissioner’s controversial expedited review system, a disputed one-day therapy clearance system that apparently troubled her former heads. “By what process are these medications being chosen for this voucher program? Who takes the calls?” Howard questioned. “There is a lot of confidentiality happening at the FDA right now.”

Broadly speaking, he stated, “the FDA appears to be shifting towards laxer rules of pharmaceuticals, aside from shots.”

Public Track Record on Immunizations

Concerning immunizations, Dr. Høeg has a clearer, if problematic, history, Howard said. She released a research paper using unverified public submissions to determine the incidence of myocarditis following COVID-19 immunization. She advised the state of Florida chief medical officer Joseph Ladapo, who allegedly have altered data to indicate COVID-19 vaccines are riskier than they are.

Part of her “desired changes” for the current administration encompassed revising guidelines for recently developed shots and ending “unnecessary” vaccines, she stated post-election on a online show. At the agency, Dr. Høeg has allegedly suggested excluding young men from obtaining Covid vaccines.

“She’s an complete true believer who commences with her beliefs and tailors the evidence to accommodate the data in a highly disingenuous, untruthful fashion,” Dr. Howard said.

Taking Control and a “Revenge Tour”

Dr. Høeg joined fellow dissenters, {like|